Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation

Blood. 2017 Jun 1;129(22):3031-3033. doi: 10.1182/blood-2017-02-766154. Epub 2017 Mar 28.

Authors

Lohith S Bachegowda¹, Rima M Saliba¹, Reshma Ramlal¹, Piyanuch Kongtim¹, Julianne Chen¹, Gabriela Rondon¹, Whitney Wallis¹, Amin Alousi¹, Sairah Ahmed¹, Chitra M Hosing¹, Simrit Parmar¹, Muzaffar Qazilbash¹, Issa F Khouri¹, Qaiser Bashir¹, Betul Oran^{1

2}, Uday Popat^{1

2}, Elizabeth J Shpall^{1

2}, David Marin^{1

2}, Katayoun Rezvani^{1

2}, Partow Kebriaei^{1

2}, Richard E Champlin^{1

2}, Stefan O Ciurea^{1

2}

Affiliations

¹ Department of Stem Cell Transplantation and Cellular Therapy and.
² Transplant Myeloid Study Group, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types

Letter

MeSH terms

Allografts
Disease-Free Survival
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / mortality
Leukemia, Myeloid, Acute* / therapy
Male
Models, Biological*
Myelodysplastic Syndromes* / mortality
Myelodysplastic Syndromes* / therapy
Predictive Value of Tests
Retrospective Studies
Survival Rate